Enovis Corp (ENOV)vsEdwards Lifesciences Corp (EW)
ENOV
Enovis Corp
$23.78
+4.02%
HEALTHCARE · Cap: $1.25B
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 177% more annual revenue ($6.30B vs $2.28B). EW leads profitability with a 17.4% profit margin vs -49.9%. ENOV appears more attractively valued with a PEG of 1.90. EW earns a higher WallStSmart Score of 61/100 (C+).
ENOV
Buy57
out of 100
Grade: C
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.9%
Fair Value
$35.03
Current Price
$23.78
$11.25 discount
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 153.1% YoY
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
Operating margin of 3.6%
ROE of -77.0% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ENOV
The strongest argument for ENOV centers on Price/Book, EPS Growth.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ENOV
The primary concerns for ENOV are PEG Ratio, Market Cap, Operating Margin.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
ENOV profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.
ENOV carries more volatility with a beta of 1.49 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
EW generates stronger free cash flow (-21M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 57/100), backed by strong 17.4% margins and 16.7% revenue growth. ENOV offers better value entry with a 34.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enovis Corp
HEALTHCARE · MEDICAL DEVICES · USA
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?